Infections in Patients with Relapsed Refractory Multiple Myeloma Receiving Idecabtagene Vicleucel Therapy: A Real-World Analysis from CIBMTR

Key Points

• Infections frequently occur in relapsed refractory multiple myeloma patients receiving idecabtagene vicleucel therapy, highlighting clinical implications.
• The analysis from the CIBMTR shows significant cases of infections among patients undergoing this treatment.
• Observational analysis involved real-world data from a substantial cohort, shedding light on the prevalence of infections.
• This study underscores the importance of vigilance regarding infections in immunocompromised patients undergoing therapy.